Open AccessAntivirals: current state of the art
Author(s) -
Erik De Clercq
Publication year - 2008
Publication title -
future virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 34
eISSN - 1746-0808
pISSN - 1746-0794
DOI - 10.2217/17460794.3.4.393
Subject(s) - virology , vaccinia , virus , varicella zoster virus , herpes simplex virus , medicine , cytomegalovirus , monkeypox , biology , viral disease , herpesviridae , biochemistry , gene , recombinant dna
Most of the antiviral agents that have been approved, and are currently used in the treatment of virus infections, are targeted at HIV, HBV, herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV) and HCV or influenza virus. Additional compounds for HIV, HBV, HSV, VZV, CMV, HCV, influenza virus and several other viral infections, for example poxvirus (e.g., variola, vaccinia and monkeypox), respiratory syncytial virus, hemorrhagic fever virus (e.g., Lassa, Rift Valley and Ebola) and enterovirus (e.g., polio, Coxsackie and echo), are still in the experimental stage, that is, under clinical or preclinical development.